Engineering allogeneic type 1 regulatory T cells: a scalable, off-the-shelf platform for restoring immune tolerance - Summary - MDSpire

Engineering allogeneic type 1 regulatory T cells: a scalable, off-the-shelf platform for restoring immune tolerance

  • By

  • Molly Javier Uyeda

  • Audrey Re

  • Chunyi Tang

  • Melissa McLaughlin

  • Daryl Humes

  • Steven Sexton

  • Robert Freeborn

  • Isaura Villalba

  • Kevin Nugent

  • James Adams

  • Jie Wei

  • Matt Breton

  • Xavier Paliard

  • Maximilian Richter

  • Maria Grazia Roncarolo

  • Ryan Bjordahl

  • July 9, 2026

  • 0 min

Share

Objective:

To develop a scalable allogeneic Type 1 regulatory T (Tr1) cell therapy, TRX103, for restoring immune tolerance in immune-mediated diseases.

Approach:
  • Clinical Trials: TRX103 is currently being evaluated in a Phase 1/2a study for treatment-refractory Crohn’s disease (NCT06721962) and a Phase I study for GvHD prevention in hematopoietic stem cell transplantation recipients (NCT06462365).
Key Findings:
  • TRX103 exhibits a distinct immunomodulatory profile with reduced expression of activation and immune synapse–associated molecules.
  • The therapy demonstrated the ability to suppress effector T cell activity and inhibit pro-inflammatory responses in both healthy and Crohn’s disease patients.
Interpretation:

The findings support the clinical development of TRX103 as a scalable allogeneic cell therapy for immune-mediated diseases.

Limitations:
  • The study primarily focuses on preclinical findings and early-phase clinical trials.
  • Further research is needed to establish long-term efficacy and safety in diverse patient populations.
Conclusion:

TRX103 represents a promising advancement in the development of allogeneic Tr1 cell therapies for restoring immune tolerance.

Original Source(s)

Engineering allogeneic type 1 regulatory T cells: a scalable, off-the-shelf platform for restoring immune tolerance

  • by Molly Javier Uyeda, Audrey Re, Chunyi Tang, Melissa McLaughlin, Daryl Humes, Steven Sexton, Robert Freeborn, Isaura Villalba, Kevin Nugent, James Adams, Jie Wei, Matt Breton, Xavier Paliard, Maximilian Richter, Maria Grazia Roncarolo, Ryan Bjordahl

  • July 9, 2026

Related Content

Comparing the efficacy and safety of nafamostat mesylate versus citrate for anticoagulation in continuous renal replacement therapy: a systematic review and meta-analysis

Case Report: Severe ANCA-positive eosinophilic granulomatosis with polyangiitis presenting with Loeffler endocarditis and cryofibrinogenemia-associated digital gangrene successfully treated with rituximab

Upregulated CD177 on neutrophils is implicated in sepsis pathogenesis and necroptosis-driven inflammation